Ensysce Biosciences (ENSC) Net Margin (2020 - 2025)
Ensysce Biosciences (ENSC) posted quarterly Net Margin of 756.26% for Q3 2025, down 77561.0% year-over-year from N/an in Q3 2024, and down 498.35% quarter-over-quarter from 126.39% in Q2 2025.
Ensysce Biosciences (ENSC) Net Margin (2020 - 2025) Analysis & Trends
Ensysce Biosciences (ENSC) has reported Net Margin for 6 consecutive years, with 756.26% the latest figure, recorded in Q3 2025.
- In Q3 2025, Net Margin fell 77561.0% year-over-year to 756.26%; the TTM figure through Sep 2025 stood at 244.49% (down 6520.0% YoY), while the FY2024 annual figure was 153.3%, up 32309.0% from the prior year.
- Net Margin slipped to 756.26% in Q3 2025 per ENSC's latest filing, from 126.39% in the prior quarter.
- Across five years, Net Margin topped out at 19.36% in Q3 2024 and bottomed at 3855.62% in Q2 2022.
- Historically, Net Margin has averaged 849.65% across 5 years, with a median of 455.88% in 2023.
- Annual changes were most pronounced in 2022 — Net Margin plunged 364515 bps — and 2023, when it jumped 339974 bps.
- Ensysce Biosciences' Net Margin stood at 662.88% in 2021, then surged by 42 bps to 385.21% in 2022, then tumbled by 77 bps to 680.4% in 2023, then jumped by 60 bps to 273.42% in 2024, then tumbled by 177 bps to 756.26% in 2025.
- Business Quant data shows ENSC's Net Margin at 756.26% in Q3 2025, 126.39% in Q2 2025, and 147.42% in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.22 Bn | 132.37 Bn | 2.84 Bn | 32.99% |
| 2 | Regeneron Pharmaceuticals | 86.29 Bn | 78.30 Bn | 3.93 Bn | 30.23% |
| 3 | Argenx Se | 65.17 Bn | 59.98 Bn | 1.37 Bn | 31.16% |
| 4 | Moderna | 61.38 Bn | 56.24 Bn | 52.00 Mn | -539.31% |
| 5 | BeOne Medicines | 42.18 Bn | 37.09 Bn | 1.53 Bn | 13.90% |
| 6 | Alnylam Pharmaceuticals | 30.99 Bn | 27.68 Bn | 992.69 Mn | 12.74% |
| 7 | BioNTech SE | 28.45 Bn | 10.05 Bn | 668.28 Mn | -16.51% |
| 8 | Insmed | 27.47 Bn | 26.31 Bn | 358.27 Mn | -3.12% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 12.09% |
| 10 | Ensysce Biosciences | 935,232.79 | -3.38 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -756.26% |
| Jun 30, 2025 | -126.39% |
| Mar 31, 2025 | -147.42% |
| Dec 31, 2024 | -273.42% |
| Sep 30, 2024 | 19.36% |
| Jun 30, 2024 | -1,082.41% |
| Mar 31, 2024 | -1,019.48% |
| Dec 31, 2023 | -680.40% |
| Sep 30, 2023 | -617.75% |
| Jun 30, 2023 | -455.88% |
| Mar 31, 2023 | -278.13% |
| Dec 31, 2022 | -385.21% |
| Sep 30, 2022 | -3,543.07% |
| Jun 30, 2022 | -3,855.62% |
| Mar 31, 2022 | -276.35% |
| Dec 31, 2021 | -662.88% |
| Sep 30, 2021 | -1,429.32% |
| Jun 30, 2021 | -210.46% |
| Mar 31, 2021 | -362.26% |
| Dec 31, 2020 | 51.38% |